40 completed, 10 recruiting, 10 terminated, 6 unknown. 71 Phase 2, 25 Phase 1, 4 Phase 3.
Follow Muscular Atrophy, Spinal: new trials by email Literature Review of Muscular Atrophy, Spinal trials Research Report on Muscular Atrophy, Spinal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I SKG0201 Injection - Spinal Muscular Atrophy 1 | Phase 1 / Phase 2 | Recruiting | Lanyue Biotech (Hangzhou) Co., Ltd. | 11 | 2026-07-15 | 2026-10-14 |
| A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs AZD9750, AZD5305 - Prostate Cancer | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 6 | 2026-01-27 | 2026-10-02 |
| TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Tulmimetostat, Darolutamide, Abiraterone - Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 181 | 2026-01-13 | 2026-11-13 |
| Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1 GB221 - Spinal Muscular Atrophy Type I | Phase 1 / Phase 2 | Recruiting | Gemma Biotherapeutics | 22 | 2026-01-06 | 2026-06-29 |
| A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy ARGX-119 IV, Placebo IV - Spinal Muscular Atrophy (SMA) | Phase 2 | Recruiting | argenx | 60 | 2025-12-19 | 2026-11-18 |
| A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy Apitegromab, Nusinersen, Risdiplam - Spinal Muscular Atrophy, SMA | Phase 2 | Recruiting | Scholar Rock, Inc. | 52 | 2025-09-15 | 2026-10-02 |
| Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy Mexiletine hydrochloride, Placebo - Spinal and Bulbar Muscular Atrophy | Phase 2 / Phase 3 | Active not recruiting | Masahisa Katsuno | 68 | 2025-02-28 | 2026-11-17 |
| An Open Label Study of Gene Therapy Product (Vesemnogene Lantuparvovec) in Spinal Muscular Atrophy vesemnogene lantuparvovec - Spinal Muscular Atrophy | Phase 1 / Phase 2 | Active not recruiting | Lantu Biopharma | 20 | 2024-10-20 | 2026-06-15 |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 3 Patients GC101 - Spinal Muscular Atrophy Type 3 | Phase 1 / Phase 2 | Recruiting | GeneCradle Inc | 21 | 2024-05-10 | 2026-11-17 |
| A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy Risdiplam - Muscular Atrophy, Spinal | Phase 2 | Completed | Hoffmann-La Roche | 11 | 2024-04-26 | 2026-06-22 |
| A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy Clenbuterol, Placebo - Spinal and Bulbar Muscular Atrophy | Phase 2 | Recruiting | Gianni Soraru | 90 | 2024-04-13 | 2024-04-15 |
| Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer Abemaciclib, Bicalutamide - Triple Negative Breast Neoplasms | Phase 2 | Recruiting | Universitaire Ziekenhuizen KU Leuven | 53 | 2024-04-08 | 2026-04-01 |
| A Study of NIDO-361 in Patients With SBMA NIDO-361, Placebo - Spinal and Bulbar Muscular Atrophy, Kennedy's Disease | Phase 2 | Completed | Nido Biosciences, Inc. | 54 | 2024-03-01 | 2026-03-03 |
| Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy NMD670, Placebo - Spinal Muscular Atrophy | Phase 2 | Completed | NMD Pharma A/S | 52 | 2023-09-21 | 2026-06-03 |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients GC101 - SMA II | Phase 1 / Phase 2 | Completed | GeneCradle Inc | 29 | 2023-08-01 | 2026-11-17 |
| Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris topical minoxidil in Acne Vulgaris - Acne Vulgaris | Phase 1 / Phase 2 | Unknown | Chang Gung Memorial Hospital | 26 | 2023-07-11 | 2023-11-03 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients AJ201, Placebo - Spinal and Bulbar Muscular Atrophy, Kennedy's Disease | Phase 1 / Phase 2 | Completed | AnnJi Pharmaceutical Co., Ltd. | 25 | 2023-02-28 | 2024-08-15 |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients GC101 - Spinal Muscular Atrophy | Phase 1 / Phase 2 | Recruiting | GeneCradle Inc | 18 | 2023-02-25 | 2026-11-17 |
| Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1 EXG001-307 injection - Spinal Muscular Atrophy Type I | Phase 1 / Phase 2 | Unknown | Guangzhou Jiayin Biotech Ltd | 12 | 2023-02-16 | 2024-09-19 |
| Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL) ANB-004, dose 1, ANB-004, dose 2, ANB-004, dose 3 - Spinal Muscular Atrophy (SMA) | Phase 1 / Phase 2 | Recruiting | Biocad | 40 | 2023-02-02 | 2024-02-22 |
Showing 20 of 71. Sign in to see all of them.
Bulbo-Spinal Atrophy, X-Linked (23) · Spinal Muscular Atrophies of Childhood (16) · Motor Neuron Disease (7) · Prostatic Neoplasms (7) · Amyotrophic Lateral Sclerosis (5) · Breast Neoplasms (3) · Muscle Cramp (2) · Neoplasm Metastasis (2) · Neuromuscular Diseases (2) · Neuromuscular Manifestations (2) · Salivary Gland Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Acne Vulgaris (1) · Adenocarcinoma (1)
Central Nervous System Diseases (71) · Spinal Cord Diseases (71) · Nervous System Diseases (70) · Neurodegenerative Diseases (70) · Neuromuscular Diseases (69) · Motor Neuron Disease (64) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (40) · Genetic Diseases, Inborn (39) · Heredodegenerative Disorders, Nervous System (39) · Genetic Diseases, X-Linked (23) · Neoplasms (13) · Neoplasms by Site (13) · Pathological Conditions, Signs and Symptoms (8) · Genital Diseases (7)
Risdiplam (7) · bicalutamide (5) · nusinersen (5) · 4-phenylbutyric acid (3) · Carnitine (3) · Hydroxyurea (3) · Valproic Acid (3) · Amifampridine (2) · Pyridostigmine Bromide (2) · apitegromab (2) · darolutamide (2) · olesoxime (2) · 4-Aminopyridine (1) · AZD5305 (1) · Adrenal Cortex Hormones (1)
Hoffmann-La Roche (8) · Biogen (4) · University of Utah (4) · GeneCradle Inc (3) · Novartis Pharmaceuticals (3) · Catalyst Pharmaceuticals, Inc. (2) · Duke University (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Scholar Rock, Inc. (2) · Stanford University (2) · Westat (2) · AnnJi Pharmaceutical Co., Ltd. (1) · AstraZeneca (1) · Biocad (1) · Centre Hospitalier RĂ©gional de la Citadelle (1)
United States (39) · Italy (20) · Germany (16) · Belgium (15) · Netherlands (12) · Canada (11) · China (11) · United Kingdom (11) · Poland (10) · France (8) · Spain (8) · Australia (6) · Japan (6) · Brazil (5) · Russia (5)
Dr Ching H. Wang (2) · Kathryn J Swoboda, M.D. (2) · Lorenzo Maggi, MD (2) · Sandra P Reyna, M.D. (2) · Amir Ali Hamidieh, MD (1) · Anna Ferrari, MD (1) · Arina V Zinkina-Orikhan, PhD (1) · Bjorn Oskarsson, MD (1) · Cheng-Lung Hsu, Profesor (1) · Claudia A. Chiriboga, MD, MPH (1) · Daniel George, MD (1)
PMID 37148485, PMID 27939059, PMID 31420846, PMID 19846582, PMID 20808854, PMID 21216197, PMID 21754985, PMID 24300782, PMID 24876969, PMID 26444282, PMID 28460889, PMID 28688787, PMID 30061431, PMID 30337273, PMID 31434793, PMID 33501671, PMID 33626251, PMID 34089650, PMID 34320287, PMID 34942136, PMID 35110415, PMID 35241644, PMID 35763114, PMID 35906608, PMID 36244364, PMID 36288197, PMID 36632180, PMID 37409780, PMID 38330285, PMID 38705943, PMID 40458203, PMID 40802943, PMID 41224659, PMID 42031429, PMID 42385757, PMID 42546251
2023 (4), 2016 (3), 2017 (3), 2014 (2), N01NS42361 (2), 2005 (1), 2015 (1), 2018 (1), 2025 (1), R01HD054599 (1)